Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Frequently asked questions
What sector does Avenue Therapeutics, Inc (ATXI) operate in?
Avenue Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Avenue Therapeutics, Inc (ATXI) current stock price?
As of the latest data, Avenue Therapeutics, Inc stock price is $0.26, with a previous close of $0.26.
What is Avenue Therapeutics, Inc (ATXI) current market capitalization?
Avenue Therapeutics, Inc market cap is approximately 848.78 thousand.
What is Avenue Therapeutics, Inc (ATXI) Earnings Per Share (EPS)?
The trailing EPS is -$0.86.
What is Avenue Therapeutics, Inc (ATXI) EBITDA?
Avenue Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -707.00 thousand.
Does Avenue Therapeutics, Inc (ATXI) pay dividends?
No. Avenue Therapeutics, Inc does not pay a dividend.
What is Avenue Therapeutics, Inc (ATXI) beta (volatility) score?
Avenue Therapeutics, Inc has a beta of -0.198, indicating lower volatility than the overall market.